IPP Bureau
NHA and NASSCOM organised a conclave on Ayushman Bharat Digital Mission
By IPP Bureau - June 15, 2022
The Ayushman Bharat Digital Mission (ABDM) aims to replicate this success in healthcare delivery by building an equitable, accessible and inclusive ecosystem
COVID is not over yet, says Union Health Minister
By IPP Bureau - June 14, 2022
Increased and timely testing will enable early identification of COVID cases and help to curb spread of the infection among the community
Dr. Bharati Pravin Pawar launches Intensified Diarrhoea Control Fortnight – 2022
By IPP Bureau - June 14, 2022
The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
Philips announces positive research results from its TOBA II BTK clinical trial
By IPP Bureau - June 14, 2022
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
.png "Thermo Fisher Scientific launches new MS-based solutions")
Thermo Fisher Scientific launches new MS-based solutions
By IPP Bureau - June 14, 2022
Thermo Scientific Direct Mass Technology mode augments Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers with charge detection capabilities
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
By IPP Bureau - June 14, 2022
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Nuvectis announces positive data for NXP900 in a preclinical model of Group 4 medulloblastoma
By IPP Bureau - June 14, 2022
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Sanofi-GSK next-gen COVID-19 booster delivers strong immune response against main variants
By IPP Bureau - June 14, 2022
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Karkinos Healthcare launched ‘Advanced Center for Cancer Diagnostics and Research’
By IPP Bureau - June 12, 2022
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
By IPP Bureau - June 12, 2022
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Alembic receives USFDA tentative approval for Dasatinib tablets
By IPP Bureau - June 12, 2022
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Strides receives USFDA approval for Ibuprofen OTC oral suspension
By IPP Bureau - June 12, 2022
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis
By IPP Bureau - June 12, 2022
Amarex Clinical Research guides its client to phase II of FDA trials
Isotopia and CPDC deliver first doses of n.c.a. Lu-177 to North American customers
By IPP Bureau - June 12, 2022
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Cantourage and Clever leaves intensify partnership for distribution of medical cannabis in Germany
By IPP Bureau - June 12, 2022
Cantourage introduces second Clever Leaves medical cannabis product to the German market
